The study found that using the company’s Accelerator Drug Development platform from Phase I through Phase III can shorten development by up to 34 months.
The facility expansion in Devens will help support growing demand for antibody-drug conjugates and add up to 70 new jobs when the new capacity comes online in June 2026.